Symbol
| CLDN9
| contributors: mct/npt - updated : 11-04-2023
|
HGNC name
| claudin 9
|
HGNC id
| 2051
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --other
|  
|
aberrant CLDN9 expression is a predictor of poor prognosis for endometrial cancer | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| could potentially be used as a diagnostic and/or prognostic marker for subtypes of pituitary adenomas ( | |
CLDN9 may be an important biomarker for invasive pituitary oncocytomas | Therapy target
|
System | Type | Disorder | Pubmed |
tumor | | | |
could potentially be used as an immunotherapy target for subtypes of pituitary adenomas |
| | |
| ENU–induced mouse mutant (nmf329) with Claudin 9 mutation exhibits recessively inherited deafness (Nakano 2009) |